Progesterone News and Research

RSS

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

10 Dec 2012

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.

29 Nov 2012

Advances in genomic techniques help understand cancer at cellular and molecular level

Cancer is a complex disease and only thanks to advances in genomic techniques have researchers begun to understand, at a cellular and molecular level, the mechanisms which are disrupted in cancer cells. This knowledge is a key prerequisite for developing effective treatment strategies.

23 Nov 2012

Potential to reduce preterm births ‘shockingly small’

If developed countries were to successfully implement five preventive interventions, only a 5% relative reduction in the preterm birth rate could be achieved by 2015, shows a study published by The Lancet.

16 Nov 2012

Auto-injector developed for women undergoing fertility treatment

A new auto-injector concept has been designed by innovative product development firm Cambridge Consultants in a bid to ease the trauma for women undergoing fertility treatment.

12 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

Study shows increased risk of local recurrence in women with triple negative breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of local recurrence than similar women whose disease is not classified as triple-negative.

1 Nov 2012

Social factors might explain racial and ethnic disparities in breast tumor aggressiveness

Racial and ethnic disparities in breast tumor aggressiveness might be explained by social factors that influence the developing tumor and place those in disadvantaged groups at higher risk for aggressive breast cancer, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Non-Hispanic black women more likely to die from breast cancer

Non-Hispanic black women diagnosed with breast cancer, specifically those with estrogen receptor-positive tumors, are at a significantly increased risk for breast cancer death compared with non-Hispanic white women.

29 Oct 2012

Austrian researchers receive $7.4 million award to verify new breast cancer pathways

The innovator's award recognises Josef Penninger's work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.

23 Oct 2012

New approach to prevention of breast cancer wins $7.4M award

A new approach to possible future prevention of breast cancer and slowing the spread of tumours has won Austrian researcher Josef Penninger, director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, a $7.4 million innovator's award to continue his research, from the USA's Congressionally Directed Medical Research Program.

22 Oct 2012

Drospirenone-containing birth control pills associated with increased risk of blood clots

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) - commonly referred to as blockage of arteries and blood clots, respectively - associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives.

20 Oct 2012

Progesterone News and Research

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Researchers investigate GPER receptor as possible new drug target for breast cancer

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

Advances in genomic techniques help understand cancer at cellular and molecular level

Potential to reduce preterm births ‘shockingly small’

Auto-injector developed for women undergoing fertility treatment

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

Study shows increased risk of local recurrence in women with triple negative breast cancer

Social factors might explain racial and ethnic disparities in breast tumor aggressiveness

Non-Hispanic black women more likely to die from breast cancer

Austrian researchers receive $7.4 million award to verify new breast cancer pathways

New approach to prevention of breast cancer wins $7.4M award

Drospirenone-containing birth control pills associated with increased risk of blood clots

Breast-feeding associated with reduced risk of ER/PR-negative breast cancer

Contraceptive patch suppresses ovulation in obese, nonobese women

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News